AKT3 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported.
AKT3 is the least studied AKT isoform. It plays an important role in brain development and is crucial for the viability of malignant glioma cells. AKT3 isoform may also be the key molecule in up-regulation and down-regulation of MMP13 via IL13.
Required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis
Interacts (via PH domain) with TCL1A; this enhances AKT3 phosphorylation and activation. Interacts with TRAF6. Interacts with KCTD20 (By similarity).
Interacts with BTBD10 (By similarity)
In adult tissues, it is highly expressed in brain, lung and kidney, but weakly in heart, testis and liver. In fetal tissues, it is highly expressed in heart, liver and brain and not at all in kidney
Binding of the PH domain to the phosphatidylinositol 3-kinase alpha (PI(3)K) results in its targeting to the plasma membrane
A syndrome characterized by megalencephaly, hydrocephalus, and polymicrogyria; polydactyly may also be seen. There is considerable phenotypic similarity between this disorder and the megalencephaly-capillary malformation syndrome.
| Cancer Type | Mutation Percentage |
|---|---|
| Central Nervous System Astrocytoma Grade Iv | 0.28% |
| Lung Adenocarcinoma | 1.31% |
| Lung Small Cell Carcinoma | 0.59% |
| Lung Squamous Cell Carcinoma | 1.09% |
| Oesophagus Adenocarcinoma | 1.86% |
| Oesophagus Squamous Cell Carcinoma | 0.35% |
| Pancreas Ductal Carcinoma | 0.98% |
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to AKT3, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 5
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT03310541 | Breast Cancer, Prostate Cancer, Advanced Solid Tumors | AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations | PHASE1 | COMPLETED |
| NCT02476955 | Solid Tumors, Ovarian Cancer, Endometrial Cancer | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | PHASE1 | TERMINATED |
| NCT06425926 | Melanoma Stage IV, Solid Tumor | Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | PHASE1, PHASE2 | RECRUITING |
| NCT01473095 | Solid Tumor, Malignant Lymphoma, Tumor | Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | PHASE1 | COMPLETED |
| NCT02761694 | Cancer, Solid Tumors | Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) | PHASE1 | TERMINATED |